KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial. PMID 35387819 · BMJ Open · 2022-Apr-06 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment-a study protocol for a randomised trial investigating a novel therapy called TAK228. PMID 35382842 · Trials · 2022-Apr-05 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. PMID 35262646 · JAMA Dermatol · 2022-Apr-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. PMID 38288923 · Lancet Rheumatol · 2022-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evaluation of increasing digestible threonine to lysine ratio in corn-soybean meal diets without and with distillers dried grains with solubles on growth performance of growing-finishing pigs. PMID 35663612 · Transl Anim Sci · 2022-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome. PMID 35648286 · Neurotherapeutics · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin. PMID 35497806 · Kidney Int Rep · 2022-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
New evidence in severe pneumonia: imipenem/ cilastatin/relebactam. PMID 35488826 · Rev Esp Quimioter · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Localized stomach cancer: Perioperative or postoperative approach? A meta-analysis of phase III studies. PMID 35475203 · JGH Open · 2022-Apr 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
JAK inhibitors and COVID-19. PMID 35459733 · J Immunother Cancer · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
HIPGEN: a randomized, multicentre phase III study using intramuscular PLacenta-eXpanded stromal cells therapy for recovery following hip fracture arthroplasty : a study design. PMID 35451865 · Bone Jt Open · 2022-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of remimazolam versus midazolam for procedural sedation: post hoc integrated analyses of three phase 3 clinical trials. PMID 35433203 · Endosc Int Open · 2022-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date? PMID 35397073 · Drugs · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
In inpatients with COVID-19 who need supplemental oxygen, lenzilumab increased ventilation-free survival. PMID 35377717 · Ann Intern Med · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Treating hypertension with a pill containing very low doses of four antihypertensive agents compared with standard dose irbesartan. PMID 35361657 · Drug Ther Bull · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The Evolving Neoadjuvant Treatment Paradigm for Patients with Locoregional mismatch Repair Proficient Rectal Cancer. PMID 35312962 · Curr Treat Options Oncol · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Intracranial Hemorrhage Following Anticoagulant Treatment in Denmark: Spontaneous Adverse Drug Reaction Reports Versus Real-World Data. PMID 35305263 · Drug Saf · 2022-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials. PMID 35303782 · Expert Rev Anticancer Ther · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features. PMID 35303549 · Cancer Treat Rev · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy-Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review. PMID 35265729 · Open Forum Infect Dis · 2022-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study. PMID 35211872 · Adv Ther · 2022-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA. PMID 35196605 · Transl Oncol · 2022-Apr The record is a policy/editorial article discussing a Phase 3 RCT (OCEAN trial) but is not an original formal-result report of the trial itself. It lacks the necessary details to confirm a drug intervention in the context of an original result report, and the report type is 'other' (editorial/commentary), not a trial result publication.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies. PMID 35184255 · Infect Dis Ther · 2022-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. PMID 35183043 · ESMO Open · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. PMID 35182247 · Int J Clin Oncol · 2022-Apr 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Should we apply a treatable traits approach to asthma care? PMID 35172180 · Ann Allergy Asthma Immunol · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
[Radiotherapy dose escalation does not improve local control in patients with esophageal cancer after definitive radiochemotherapy: the ARTDECO randomized phase III trial]. PMID 35166870 · Strahlenther Onkol · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Review article: emerging drug therapies in inflammatory bowel disease. PMID 35166398 · Aliment Pharmacol Ther · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer. PMID 35152172 · Lung Cancer · 2022-Apr 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia. PMID 35134259 · Hepatol Res · 2022-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Moderately hypofractionated post-operative radiation therapy for breast cancer: Systematic review and meta-analysis of randomized clinical trials. PMID 35131647 · Breast · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis. PMID 35088508 · Dermatol Ther · 2022-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]. PMID 35086737 · Ann Oncol · 2022-Apr The record is a corrigendum (erratum) to a Phase III RCT. The metadata confirms it is oncology, randomized, and Phase III, but it is not an original result report and does not contain time-to-event efficacy data itself. The original trial (ITACA) is eligible, but this specific record is a secondary administrative document.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. PMID 34974527 · Leukemia · 2022-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Restricted survival benefit with right-censored data. PMID 34970772 · Biom J · 2022-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. PMID 34970731 · Rheumatol Ther · 2022-Apr The study is a non-oncology safety analysis for psoriatic arthritis. It is a randomized, Phase 3 drug trial, but it is excluded because it is not an oncology study, and it does not report a primary or key secondary time-to-event efficacy endpoint for a malignant neoplasm.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials. PMID 34940983 · Hematol Oncol · 2022-Apr The record describes a network meta-analysis focused on the safety endpoint of cardiotoxicity. It does not report primary or key secondary time-to-event efficacy endpoints (like OS, PFS) from an original randomized trial, making it ineligible.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials. PMID 34866291 · Diabetes Obes Metab · 2022-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Leap from TACE to TACE Potentiated by Immune Response Modulation and Angiogenesis Inhibition for Patients with Intermediate-Stage Hepatocellular Carcinoma: LEAP-012 Phase 3 Randomized Control Trial Protocol. PMID 34853874 · Cardiovasc Intervent Radiol · 2022-Apr 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. PMID 34798201 · J Am Acad Dermatol · 2022-Apr The study is a phase 3 randomized trial of a drug (guselkumab) in humans, but the indication is psoriasis, a non-oncologic disease. The abstract explicitly evaluates and reports safety outcomes (adverse event rates) and does not mention or present any primary or key secondary time-to-event efficacy endpoints such as OS, PFS, DFS, EFS, RFS, TTP, or associated Kaplan-Meier plots or hazard ratios. Therefore, it does not meet the oncology-specific and time-to-event efficacy criteria for inclusion.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia. PMID 34786648 · Adv Ther · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. PMID 34758945 · Clin Lymphoma Myeloma Leuk · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data. PMID 34695400 · Am J Ophthalmol · 2022-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men. PMID 34678491 · Contemp Clin Trials · 2022-Apr 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen. PMID 34678128 · Ann Am Thorac Soc · 2022-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. PMID 34599979 · J Allergy Clin Immunol · 2022-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria. PMID 34590409 · Alzheimers Dement · 2022-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials. PMID 34459002 · Allergy · 2022-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. PMID 34449295 · Mult Scler · 2022-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2. PMID 34420143 · Qual Life Res · 2022-Apr The record describes a methodological study on missing data for adverse event reporting in two phase III oncology trials. While the underlying trials are oncology, randomized, phase III, and drug-interventional, this specific publication does not present the primary or key secondary time-to-event efficacy results (e.g., OS, PFS) from those trials. It is a secondary analysis focused on statistical methods for PRO-CTCAE data, which falls under the 'other' report type for this adjudication context and is excluded.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -